Wegovy has been approved for use as a heart disease prevention medication, the FDA announced on Friday. The injectable semaglutide — originally approved for weight loss for certain patients — is now ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved once-weekly semaglutide 2.4 mg to reduce CV risk for adults with obesity and preexisting CVD.
Please provide your email address to receive an email when new articles are posted on . A new generation of obesity drugs is changing the treatment landscape for patients and providers, with options ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results